Beam Therapeutics (BEAM) Stock Price, News & Analysis

Company Overview

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $13.53 to $16.04
• 50-Day Range: $15.27 to $34.16
• 52-Week Range: $13.53 to $35.25
• Volume: 4.47 million shs
• Average Volume: 1.35 million shs
• Market Capitalization: $1.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.45
• Consensus Rating: Buy

Beam Therapeutics Stock Analysis - MarketRank™

Beam Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 342nd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Beam Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beam Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beam Therapeutics are expected to grow in the coming year, from ($4.57) to ($4.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beam Therapeutics is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beam Therapeutics is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beam Therapeutics has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.33% of the float of Beam Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Beam Therapeutics has recently increased by 21.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Beam Therapeutics does not currently pay a dividend.

Dividend Growth

Beam Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.33% of the float of Beam Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Beam Therapeutics has recently increased by 21.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.40

News Sentiment

Beam Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Beam Therapeutics this week, compared to 7 articles on an average week.

Search Interest

19 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.

MarketBeat Follows

9 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,605,698.00 in company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Beam Therapeutics is held by insiders.

Percentage Held by Institutions

99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BEAM Stock Analysis - Frequently Asked Questions

How have BEAM shares performed this year?

Beam Therapeutics' stock was trading at $24.80 at the beginning of 2025. Since then, BEAM stock has decreased by 38.3% and is now trading at $15.30.
View the best growth stocks for 2025 here.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.09) earnings per share for the quarter, topping analysts' consensus estimates of ($1.25) by $0.16. Beam Therapeutics's quarterly revenue was down 90.5% on a year-over-year basis.

Does Beam Therapeutics have any subsidiaries?

The following companies are subsidiaries of Beam Therapeutics: Blink Therapeutics Inc..

When did Beam Therapeutics IPO?

Beam Therapeutics (BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' top institutional investors include GAMMA Investing LLC (0.04%). Insiders that own company stock include Fmr Llc, John M Evans, Giuseppe Ciaramella, Christine Bellon, Terry-Ann Burrell, Amy Simon and Bethany J Cavanagh.
View institutional ownership trends.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 2/25/2025
• Today: 4/07/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BEAM
• CIK: 1745999
• Web: www.beamtx.com
• Phone: 857-327-8775
• Fax: N/A
• Employees: 510
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $49.45
• High Stock Price Target: $80.00
• Low Stock Price Target: $26.00
• Potential Upside/Downside: +223.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-132,530,000.00
• Net Margins: -41.07%
• Pretax Margin: -40.67%
• Return on Equity: -16.22%
• Return on Assets: -10.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.69

Sales & Book Value

• Annual Sales: $63.52 million
• Price / Sales: 24.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.04 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 99,785,000
• Free Float: 79,328,000
• Market Cap: $1.53 billion
• Optionable: Optionable
• Beta: 2.02